Raunio, Anna
Kaivola, Karri
Tuimala, Jarno
Kero, Mia
Oinas, Minna
Polvikoski, Tuomo
Paetau, Anders
Tienari, Pentti J.
Myllykangas, Liisa http://orcid.org/0000-0002-2237-5466
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (294817)
Helsingin ja Uudenmaan Sairaanhoitopiiri (TYH2018217)
Medicinska Understödsföreningen Liv och Hälsa
Sigrid Juséliuksen Säätiö
Finska Läkaresällskapet
Suomen Kulttuurirahasto
Article History
Received: 26 June 2019
Revised: 17 August 2019
Accepted: 30 August 2019
First Online: 7 September 2019
Compliance with ethical standards
:
: Pentti J. Tienari holds patent on C9orf72 in diagnostics and treatment of ALS/FTD and has made paid consultations to Roche, Biogen, Merck, Teva, Sanofi-Genzyme and Novartis. Other authors declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants or their relatives.